MONMOUTH JUNCTION, N.J.,
Feb. 4, 2016 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO), a critical care
immunotherapy leader commercializing its flagship CytoSorb® blood
filter to treat deadly inflammation in critically-ill and cardiac
surgery patients around the world, announced that CEO Dr.
Phillip Chan, MD, PhD, will present
at the Source Capital Group's 2016 Disruptive Growth &
Healthcare Conference, providing an overview and update on the
company.
Conference Presentation
Details:
Where: Convene Conference Center, 730
Third Avenue, New York, NY
10017
When: Wednesday, February 10, 2016 at 8:30 AM ET
Room: Nolita Room
Conference Website: www.sourcecapitalconference.com
Currently, the management team is scheduling one-on-one meetings
with registered investors through the conference's meeting
portal. To confirm, please contact Ms. Amy Vogel at avogel@cytosorbents.com
About Source Capital Group's 2016 Disruptive Growth &
Healthcare Conference
The 2016 Disruptive Growth & Healthcare Conference will
feature presentations from CEOs, CFOs, COOs and CMOs of life
science companies focusing on solutions to unmet medical needs and
growth companies with disruptive technologies and business models.
Attendees will include over 400 institutional investors, accredited
investors, family offices, analysts, registered investment
advisors, wealth managers, Source reps and their clients. The
panels will cover regenerative medicine, immunotherapy,
diagnostics, disruptive innovations and business models, disruptive
holding companies, energy – clean tech, technology media &
telecom (TMT), and finally a discussion regarding NOLs and
rights offerings. Presently Source has 8 offices, approximately 100
registered representatives, $750
million in assets, 10,000 retail accounts and is a SEC
registered investment advisor. The conference is open to all
Financial Advisors, Wealth Managers, Family Offices, Sell-Side
Analysts, Institutional Investors, Accredited Investors, and
Clients.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorb® is approved in the European Union with distribution in
32 countries around the world, as a safe and effective
extracorporeal cytokine adsorber, designed to reduce the "cytokine
storm" or "cytokine release syndrome" that could otherwise cause
massive inflammation, organ failure and death in common critical
illnesses such as sepsis, burn injury, trauma, lung injury, and
pancreatitis, as well as in cancer immunotherapy. These are
conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorb® is also being
used during and after cardiac surgery to remove inflammatory
mediators, such as cytokines and free hemoglobin, which can lead to
post-operative complications, including multiple organ
failure. CytoSorb® has been used safely in more than 9,000
human treatments to date.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. The Company has numerous products under
development based upon this unique blood purification technology,
protected by 32 issued U.S. patents and multiple applications
pending, including HemoDefend™, ContrastSorb, DrugSorb, and others.
Additional information is available for download on the Company's
websites: http://www.cytosorbents.com and
http://www.cytosorb.com
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 31, 2015, as updated by the risks reported in
our Quarterly Reports on Form 10-Q, and in the press releases and
other communications to shareholders issued by us from time to time
which attempt to advise interested parties of the risks and factors
which may affect our business. We caution you not to place undue
reliance upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow Us on Facebook and
Twitter
Cytosorbents Contact:
Amy Vogel
Investor Relations
(732) 329-8885 ext. *825
avogel@cytosorbents.com
Investor Contact:
Lee Roth
The Ruth Group
646-536-7012
lroth@theruthgroup.com
Public Relations Contact:
Eric Kim
The Ruth Group
646-536-7023
ekim@theruthgroup.com
Logo -
http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-to-present-at-source-capital-groups-2016-disruptive-growth--healthcare-conference-300215201.html
SOURCE CytoSorbents Corporation